Evidence map›Paper›PMID 30128025›Full record

ArticleOncology letters2018

Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.

Zhilan Li, Xiudi Jiang, Peihong Chen, Xuebing Wu, Aihua Duan, Yiyu Qin

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. The Changing Face ofFrontiers in surgery · 2020
    Pooled it
  2. Review
  3. Somatostatin and Somatostatin Receptors in Tumour Biology.International journal of molecular sciences · 2023
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zhilan LiDepartment of Clinical Laboratory, The Seventh People's Hospital of Shanghai, Shanghai 200137, P.R. China.
Xiudi JiangDepartment of Clinical Laboratory, The Seventh People's Hospital of Shanghai, Shanghai 200137, P.R. China.
Peihong ChenDepartment of Clinical Laboratory, The Seventh People's Hospital of Shanghai, Shanghai 200137, P.R. China.
Xuebing WuDepartment of Blood Transfusion, The Seventh People's Hospital of Shanghai, Shanghai 200137, P.R. China.
Aihua DuanDepartment of Clinical Laboratory, The Seventh People's Hospital of Shanghai, Shanghai 200137, P.R. China.
Yiyu QinResearch Centre of Biomedical Technology, Clinic Medical College, Jiangsu Vocational College of Medicine, Yancheng, Jiangsu 224005, P.R. China.
Seventh People's Hospital of Shanghai · CNJiangsu Vocational College of Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic thyroid cancer (ATC) represents the most aggressive subtype of thyroid cancer and has a poor prognosis. In addition to surgery, chemotherapy is an important treatment for ATC; however, the therapeutic effects of current chemotherapies for ATC are not particularly promising. There is a high proportion of side population (SP) cells in ATC, which may be a reason for its drug resistance. In the present study, the antitumor activities of combined octreotide (OCT) and cisplatin (DDP) on the proliferation and apoptosis of ATC SP cells were evaluated. First, SP cells from 8305C and BHT101 cell lines were detected and sorted. Following

Indexed as

cisplatinoctreotideside populationthyroid carcinoma

Identifiers

PMID30128025
PMCPMC6096104
OpenAlexW2832196930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.